JP2020504719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504719A5 JP2020504719A5 JP2019532076A JP2019532076A JP2020504719A5 JP 2020504719 A5 JP2020504719 A5 JP 2020504719A5 JP 2019532076 A JP2019532076 A JP 2019532076A JP 2019532076 A JP2019532076 A JP 2019532076A JP 2020504719 A5 JP2020504719 A5 JP 2020504719A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cadherin
- expression
- depigmentation
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306719 | 2016-12-16 | ||
| EP16306719.2 | 2016-12-16 | ||
| PCT/EP2017/083182 WO2018109222A1 (en) | 2016-12-16 | 2017-12-15 | Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504719A JP2020504719A (ja) | 2020-02-13 |
| JP2020504719A5 true JP2020504719A5 (https=) | 2020-12-03 |
| JP7141397B2 JP7141397B2 (ja) | 2022-09-22 |
Family
ID=57680192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532076A Active JP7141397B2 (ja) | 2016-12-16 | 2017-12-15 | Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10894837B2 (https=) |
| EP (1) | EP3555138A1 (https=) |
| JP (1) | JP7141397B2 (https=) |
| CN (1) | CN110312737A (https=) |
| BR (1) | BR112019012253A2 (https=) |
| WO (1) | WO2018109222A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022061351A1 (en) * | 2020-09-16 | 2022-03-24 | Incyte Corporation | Topical treatment of vitiligo |
| US20240285497A1 (en) | 2021-02-26 | 2024-08-29 | National University Corporation Kobe University | Method for evaluating an ability of a test sample to trigger a foreign body reaction in the skin, a method for screening a substance having an ability to inhibit a foreign body reaction in the skin, and an agent for inhibiting a foreign body reaction in the skin |
| WO2024028417A1 (en) * | 2022-08-03 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | New composition for the treatment and/or prevention of vitiligo |
| CN119236080A (zh) * | 2024-09-29 | 2025-01-03 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 一种医药组合物在制备用于治疗多发性硬化药物中的应用 |
| CN120945015B (zh) * | 2025-10-17 | 2025-12-23 | 潍坊市人民医院(潍坊市公共卫生临床中心、潍坊市职业病医院) | 一种适用于黑色素瘤基因检测的脱色素方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59708838D1 (de) | 1996-08-30 | 2003-01-09 | Jens Peter Fuerste | Spiegelselektion und spiegelevolution von nucleinsäuren |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US20040053876A1 (en) | 2002-03-26 | 2004-03-18 | The Regents Of The University Of Michigan | siRNAs and uses therof |
| US8101348B2 (en) | 2002-07-10 | 2012-01-24 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | RNA-interference by single-stranded RNA molecules |
| WO2006037513A1 (en) * | 2004-10-09 | 2006-04-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9) |
| EP2395996A1 (en) * | 2009-02-13 | 2011-12-21 | Indiana University Research and Technology Corporation | Compounds and methods for inhibiting mmp2 and mmp9 |
| EP2608809B1 (en) | 2010-08-27 | 2019-05-22 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
| WO2013130078A1 (en) | 2012-02-29 | 2013-09-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
| FR3015986A1 (fr) | 2013-12-30 | 2015-07-03 | Lvmh Rech | Aptameres inhibiteurs de l'activite enzymatique de la proteine mmp-9 |
| EP2985295A1 (en) | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
| EP2985296A1 (en) | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
-
2017
- 2017-12-15 US US16/469,665 patent/US10894837B2/en active Active
- 2017-12-15 CN CN201780078081.9A patent/CN110312737A/zh active Pending
- 2017-12-15 EP EP17836013.7A patent/EP3555138A1/en active Pending
- 2017-12-15 JP JP2019532076A patent/JP7141397B2/ja active Active
- 2017-12-15 BR BR112019012253A patent/BR112019012253A2/pt unknown
- 2017-12-15 WO PCT/EP2017/083182 patent/WO2018109222A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504719A5 (https=) | ||
| Shi et al. | Interstitial flow promotes vascular fibroblast, myofibroblast, and smooth muscle cell motility in 3-D collagen I via upregulation of MMP-1 | |
| NO20071240L (no) | Terapeutiske anvendelser av RTP801 inhibitorer | |
| Hedges et al. | An open trial of nefazodone in adult patients with generalized anxiety disorder | |
| Peng et al. | The effect of hyperbaric oxygen on intracephalic angiogenesis in rats with intracerebral hemorrhage | |
| Zhou et al. | Musk ketone induces neural stem cell proliferation and differentiation in cerebral ischemia via activation of the PI3K/Akt signaling pathway | |
| EA201300213A1 (ru) | Применение ингибиторов dpp iv | |
| Chen et al. | Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling | |
| EA201000365A1 (ru) | Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза | |
| ATE489957T1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| Yeh et al. | Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities | |
| Shan et al. | Naringenin attenuates fibroblast activation and inflammatory response in a mechanical stretch-induced hypertrophic scar mouse model | |
| Wang et al. | Allicin protects traumatic spinal cord injury through regulating the HSP70/Akt/iNOS pathway in mice | |
| DK2903616T3 (da) | Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer | |
| Fang et al. | Neuroprotective effects and dynamic expressions of MMP9 and TIMP1 associated with atorvastatin pretreatment in ischemia–reperfusion rats | |
| Chun et al. | Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats | |
| Akagi et al. | Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension | |
| CL2021003543A1 (es) | Tratamiento y diagnóstico de desórdenes inflamatorios (divisional de la solicitud no. 201802097) | |
| MX340231B (es) | Enzimas fluidas incubadas y usos de las mismas. | |
| Yao et al. | The Notch pathway mediates the angiotensin II-induced synthesis of extracellular matrix components in podocytes | |
| Sinno et al. | The matrix metalloproteinase inhibitor marimastat promotes neural progenitor cell differentiation into neurons by gelatinase-independent TIMP-2-dependent mechanisms | |
| Liu et al. | Davallia bilabiata exhibits anti-angiogenic effect with modified MMP-2/TIMP-2 secretion and inhibited VEGF ligand/receptors expression in vascular endothelial cells | |
| CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
| Jiang et al. | Aspirin inhibits LPS-induced expression of PI3K/Akt, ERK, NF-κB, CX3CL1, and MMPs in human bronchial epithelial cells | |
| Kim et al. | Suppression of TPA-induced tumor cell invasion by sulfuretin via inhibition of NF-κB-dependent MMP-9 expression |